Business
Zero Candida Technologies Reports Full Year 2024 Financial Results and Business Highlights
Zero Candida Technologies Reports Full Year 2024 Financial Results and Business Highlights ...
About this update from Zero Candida Technologies Inc.
[{"type":"text","content":"\n\n\n\n Zero Candida Technologies Reports Full Year 2024 Financial Results and Business Highlights\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n April 2, 2025\n \n\n /CNW/ --\n \n\n Zero Candida Technologies, Inc\n \n\n . (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the \"Company\" or \"ZCT\"), a FemTech medical device company revolutionizing women's health, reports financial results and key business achievements for the year ended\n \n December 31, 2024\n \n . These results are presented in accordance with the International Financial Reporting Standard (IFRS) as issued by the International Accounting Standards Board. This release should be read in conjunction with the Company's audited consolidated financial statements and associated Management Discussion and Analysis (\"MD&A\"), available on SEDAR\n \n\n www.sedarplus.ca\n \n\n . In addition, the company announced today that Ms.\n \n Orit Berger\n \n has resigned from its Board of Directors (the \"Board\") for personal reasons, effective immediately.\n \n\n\n\n\n \"2024 was a transformative year for Zero Candida. We achieved key pre-clinical milestones, completed our public listing, and are now well-positioned to accelerate our development plans. Looking ahead, we are focused on advancing towards clinical trials and bringing our groundbreaking device for Candidiasis to market, addressing a critical unmet need in women's health,\" commented Eli Ben Haroosh, Zero Candida's CEO. \"Our financial results align with our expectations as a development-stage company, and we believe the progress we made this year positions us for long-term success.\"\n \n\n\n Business Highlights\n \n\n\n The following summarizes key business developments from the twelve months ended\n \n December 31, 2024\n \n , to the date of this release:\n \n\n\n In\n \n March 2024\n \n , the Company formalized its Business Combination Agreement with ZC. This agreement initiated the process to acquire 100% of ZC's issued and outstanding securities, in exchange for the Company issuin...